Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:IPA
DateTimeSourceHeadlineSymbolCompany
09/05/202214:18InvestorsHub NewsWireIPA's Subsidiary BioStrand Secures Second VLAIO Research GrantTSXV:IPAImmunoPrecise Antibodies Ltd
14/04/202213:06InvestorsHub NewsWireIPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and OfferingsTSXV:IPAImmunoPrecise Antibodies Ltd
29/03/202216:48InvestorsHub NewsWireIPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial IntelligenceTSXV:IPAImmunoPrecise Antibodies Ltd
14/03/202213:04InvestorsHub NewsWireIPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of DefenseTSXV:IPAImmunoPrecise Antibodies Ltd
09/03/202213:07InvestorsHub NewsWireIPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03TSXV:IPAImmunoPrecise Antibodies Ltd
08/04/202113:08InvestorsHub NewsWireImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's DiseaseTSXV:IPAImmunoPrecise Antibodies Ltd
13/02/202106:25PR Newswire (Canada)TSX Venture Exchange Stock Maintenance BulletinsTSXV:IPAImmunoPrecise Antibodies Ltd
23/12/202012:30PR Newswire (Canada)ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock ExchangeTSXV:IPAImmunoPrecise Antibodies Ltd
21/12/202013:12PR Newswire (Canada)ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal YearTSXV:IPAImmunoPrecise Antibodies Ltd
14/12/202012:20PR Newswire (Canada)ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine CandidateTSXV:IPAImmunoPrecise Antibodies Ltd
11/12/202012:45PR Newswire (Canada)ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2TSXV:IPAImmunoPrecise Antibodies Ltd
25/11/202018:46PR Newswire (Canada)ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™TSXV:IPAImmunoPrecise Antibodies Ltd
23/11/202012:00PR Newswire (Canada)IPA Selects Polytope™ Formulations for Pre-Clinical StudiesTSXV:IPAImmunoPrecise Antibodies Ltd
19/11/202012:00PR Newswire (Canada)ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious DiseaseTSXV:IPAImmunoPrecise Antibodies Ltd
18/11/202001:01PR Newswire (Canada)ImmunoPrecise Antibodies Confirms Effective Date of Share ConsolidationTSXV:IPAImmunoPrecise Antibodies Ltd
09/11/202014:11PR Newswire (Canada)ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration StatementTSXV:IPAImmunoPrecise Antibodies Ltd
05/11/202000:08PR Newswire (Canada)ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq ListingTSXV:IPAImmunoPrecise Antibodies Ltd
03/11/202012:30PR Newswire (Canada)ImmunoPrecise Antibodies and Mila Announce Strategic AI PartnershipTSXV:IPAImmunoPrecise Antibodies Ltd
27/10/202011:28PR Newswire (Canada)ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic ProductsTSXV:IPAImmunoPrecise Antibodies Ltd
08/10/202012:30PR Newswire (Canada)IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic TestTSXV:IPAImmunoPrecise Antibodies Ltd
06/10/202012:30PR Newswire (Canada)IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN TelevisionTSXV:IPAImmunoPrecise Antibodies Ltd
05/10/202012:30PR Newswire (Canada)ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & FriendsTSXV:IPAImmunoPrecise Antibodies Ltd
29/09/202014:10PR Newswire (Canada)ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021TSXV:IPAImmunoPrecise Antibodies Ltd
28/09/202016:59PR Newswire (Canada)IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg TelevisionTSXV:IPAImmunoPrecise Antibodies Ltd
28/09/202012:30PR Newswire (Canada)ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor DayTSXV:IPAImmunoPrecise Antibodies Ltd
25/09/202012:30PR Newswire (Canada)ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical TrialsTSXV:IPAImmunoPrecise Antibodies Ltd
22/09/202012:30PR Newswire (Canada)IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select ™TSXV:IPAImmunoPrecise Antibodies Ltd
17/09/202012:30PR Newswire (Canada)ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with ZymeworksTSXV:IPAImmunoPrecise Antibodies Ltd
10/09/202012:30PR Newswire (Canada)ImmunoPrecise Commences Application Process to Dual List on NASDAQTSXV:IPAImmunoPrecise Antibodies Ltd
09/09/202022:37PR Newswire (Canada)ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 202...TSXV:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:TSXV:IPA